Nyrada Inc. Stock

NYR

AU0000070195

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:11 2026-10-16 EDT			5-day change	1st Jan Change
0.4700 ^AUD	+9.30%		-2.08%	-58.04%

10-15	Nyrada Activates Four Clinical Trial Sites; Shares Up 7%	MT
10-12	Nyrada Receives Supportive FDA Feedback on Heart Protection Drug Candidate	MT

Last Transcript: Nyrada Inc.

Nyrada Inc. - Special Call

02-04

More transcripts

Managers and Directors: Nyrada Inc.

Manager	Title	Age	Since
James Bonnar CEO	Chief Executive Officer	-	2018-01-31
Alexandra Suchowerska CTO	Chief Tech/Sci/R&D Officer	-	-
Benjamin Evison CTO	Chief Tech/Sci/R&D Officer	-	2019-08-23

Director	Title	Age	Since
John Moore CHM	Chairman	61	2019-07-15
Marcus Frampton BRD	Director/Board Member	46	2019-05-31
James Bonnar BRD	Director/Board Member	-	2025-10-07

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NYRADA INC.	+9.30%	-2.08%	+23.68%	+2,138.10%	80.97M
WUXI APPTEC CO., LTD.	-6.60%	-8.56%	+42.79%	+64.16%	65B
ARGENX SE	-4.09%	-0.11%	+2.31%	+54.81%	51.19B
LONZA GROUP AG	+0.03%	+5.56%	+10.18%	+41.75%	51.2B
IQVIA HOLDINGS INC.	-1.53%	+2.70%	+29.72%	+34.13%	43.93B
BEONE MEDICINES AG	-1.34%	+4.12%	+16.05%	+112.18%	41.96B
REVOLUTION MEDICINES, INC.	-5.97%	-6.22%	+258.21%	+421.57%	38.14B
CELLTRION, INC.	+6.53%	+8.02%	+15.74%	+53.94%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+31.48%	-1.63%	25.2B
BIONTECH SE	-2.76%	-9.54%	-16.53%	-9.55%	22.03B
Average	-0.73%	-1.71%	+41.36%	+290.95%	37.2B
Weighted average by Cap.	-2.29%	-1.21%	+43.56%	+89.02%

See all sector performances

Nyrada Inc. is an Australia-based biotechnology company. The Company is focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Companyâ€™s lead candidate, Xolatryp, is a small molecule cardio protection and neuroprotection therapy. Xolatryp has demonstrated preclinical efficacy as an acute treatment following ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction (AMI). Xolatryp, is also a novel blocker targeting TRPC 3/6/7 ion channels, developed to mitigate secondary brain injury and prevent further brain cell death. The critical role of TRPC 3/6/7 channels in secondary injury has been validated in animal knockout models and through research-grade blockers. Its medical programs include Myocardial Ischemia and Arrhythmia Control, Stroke, and Traumatic Brain Injury.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-16	A$0.4700	+9.30%	151,844
26-10-15	A$0.4300	-10.42%	305,758
26-10-14	A$0.4800	+4.35%	333,261
26-10-13	A$0.4600	-4.17%	136,662
26-10-12	A$0.4800	0.00%	279,994

Delayed Quote Australian S.E.

More quotes

As early as today, start finding the best investment opportunities!

Market Cap	116M 80.97M 71.97M 66.71M 60.69M 115M 7.68B 802M 314M 4.01B 304M 297M 12.78B	P/E 2025	-9.91x	P/E 2026	-16.4x
Enterprise Value	108M 75.14M 66.79M 61.9M 56.32M 106M 7.13B 744M 292M 3.72B 282M 276M 11.86B	EV / Sales 2025	19.9x	EV / Sales 2026	51.1x
Free-Float	44.94%	Yield 2025 *	-	Yield 2026	-

10-15	Nyrada Activates Four Clinical Trial Sites; Shares Up 7%	MT
10-12	Nyrada Receives Supportive FDA Feedback on Heart Protection Drug Candidate	MT
09-30	Nyrada Secures US Patent for Heart Protection Drug Candidate	MT
08-20	Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%	MT
08-17	Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
07-26	Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive	MT
07-05	Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate	MT
06-15	Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion	MT
06-03	Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate	MT
05-20	Nyrada Says 7 Million Unlisted Options Due to Expire in June; Shares Fall 3%	MT
05-19	Nyrada Says Rodent Study Shows Drug Candidate's Anti-Tumor Activity, Shares Up 14%	MT
05-19	Nyrada seeks trading halt	RE
04-21	Nyrada Confirms Activation of First Site in Phase 2a Study of Drug Candidate for Heart Muscle Cell Damage	MT

22-07-25	Nyrada : Quarterly Activities Report and Appendix 4C	PU
22-06-05	Nyrada : Brain Injury Program Target Unveiled and Phase I Update	PU
22-04-18	Nyrada : Quarterly Activities Report & Appendix 4C	PU
22-03-01	Nyrada : Presentation to Meet the CEO Life Sciences Edition	PU
22-01-20	Nyrada : Quarterly Activities Report & Appendix 4C	PU

1 day	+9.30%
1 week	-2.08%
Current month	-6.00%
1 month	-35.62%
3 months	-6.00%
6 months	-20.34%
Current year	-58.04%

1 week	0.43	0.51
1 month	0.43	0.68
Current year	0.39	1.44
1 year	0.32	1.44
3 years	0.02	1.44
5 years	0.02	1.44
10 years	0.02	1.44

Nyrada Inc. Stock

Stocks

NYR

AU0000070195

Biotechnology & Medical Research

Valuation: Nyrada Inc.

Chart: Nyrada Inc.

Latest news: Nyrada Inc.

Last Transcript: Nyrada Inc.

Press Releases: Nyrada Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Nyrada Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/9/26	John Moore	Buy	Chairman	1,000,000	0.9142%
2/20/26	Rüdiger Weseloh	Free	Director	600,000	0.5485%
2/20/26	Christopher Cox	Free	Director	600,000	0.5485%

	2025	2026
Net sales	2.4M 1.67M 1.48M 1.37M 1.25M 2.36M 158M 16.52M 6.48M 82.59M 6.26M 6.13M 263M	2.01M 1.4M 1.24M 1.15M 1.05M 1.98M 133M 13.86M 5.43M 69.31M 5.25M 5.14M 221M
Net income	-4.85M -3.37M -3M -2.78M -2.53M -4.77M -320M -33.39M -13.09M -167M -12.65M -12.38M -532M	-6.56M -4.56M -4.06M -3.76M -3.42M -6.45M -433M -45.18M -17.72M -226M -17.12M -16.76M -720M
Net Debt	-2.93M -2.04M -1.81M -1.68M -1.53M -2.88M -194M -20.19M -7.92M -101M -7.65M -7.49M -322M	-8.38M -5.83M -5.19M -4.81M -4.37M -8.25M -554M -57.78M -22.65M -289M -21.89M -21.43M -921M